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Riera et al. identify a neuroendocrine circuit that controls longevity and the age-dependent onset of
metabolic decline via the pain-transducing channel TRPV1. Thus, pharmacological inhibition of
TRPV1 may provide a new approach to treat not only metabolic disorders but also a broader range
of age-related pathologies.Societies are currently facing a dramatic
demographic change with an ever-
increasing life expectancy. This is associ-
ated with a steady rise in age-related
diseases, such as type 2 diabetes melli-
tus, neurodegenerative disorders, and
malignancies. The recent identification of
molecular pathways that control the aging
process and thus lifespan provides new
therapeutic targets for the prevention
and treatment of these diseases. In
particular, metabolic signaling pathways,
such as the insulin/IGF-1/FOXO signaling
cascade, offer an evolutionary conserved
target to regulate aging and the onset of
aging-associated diseases. In this line,
the work of Riera et al. (2014) in this issue
of Cell, sheds light on a new mechanism
that relays the crosstalk between aging
and metabolism. The authors unravel a
new role for the capsaicin receptor (the
transient receptor potential cation chan-
nel subfamily V member 1, TRPV1) in the
regulation of health- and lifespan. TRPV1
predominantly resides on sensory neu-
rons of the ‘‘pain pathway,’’ where it
senses noxious stimuli such as heat,
extracellular acidification, and capsaicin,
the pungent component of chili peppers.
Along with its key function as a molecular
integrator of pain signaling, TRPV1-defi-
cient mice display an impairment of
nociception and pain sensation (Caterina
et al., 2000). In addition to hypoalgesia,
TRPV1 deficiency also protects from
diet-induced obesity (Motter and Ahern,
2008), pointing toward a dual role of1004 Cell 157, May 22, 2014 ª2014 Elsevier ITRPV1 in pain sensitivity as well as in
metabolic regulation.
The implication of sensory perception in
longevity has previously been reported in
bothworms and flies (Alcedo andKenyon,
2004; Libert et al., 2007). Alterations of
both olfactory and taste perception affect
lifespan in C. elegans and Drosophila.
Riera et al. (2014) reveal an evolutionary
conserved role for sensory perception
via the TRPV1 channel in the regulation
of lifespan, metabolic disease, and cogni-
tion. They demonstrate that mutation
of the trpv1 gene in mice or of its ortho-
logs osm-9/ocr-2 in C. elegans increases
longevity in both species. The only limita-
tion of the longevity study in mice stems
from the use of isogenic controls rather
than control littermates for the TRPV1
conventional knockout. The authors do,
however, provide convincing support,
based on SNP genotyping, that the con-
trols are 100% genetically identical to
the knockout animals.
The authors further reveal that TRPV1
activation limits lifespan via calcium-
dependent activation of calcineurin/
CRTC1/CREB signaling in worms and
TRPV1-dependent CREB regulation is
conserved in dorsal root ganglia neu-
rons of mice (Figure 1). Given the previ-
ous demonstration that CRTC1-depen-
dent CREB signaling controls lifespan
in C. elegans (Mair et al., 2011), the pre-
sent study reveals a (patho)-physiologi-
cally relevant upstream regulator of this
pathway.nc.While the majority of studies investi-
gating the interplay between longevity
and metabolism reveal an important role
of impaired action of GH/IGF-1 (growth
hormone/insulin-like growth factor) in pro-
moting longevity, the lifespan-extending
effect of TRPV1 deficiency appears to
be GH- and IGF-1-independent. Thus,
the TRPV1-deficient mice provide a rare
example of extended longevity in the
presence of normal somatic growth.
Instead, Riera and coworkers elegantly
describe a new neuroendocrine path-
way in control of age-related deteriora-
tion of metabolism and longevity. They
demonstrate that TRPV1 receptors con-
trol the release of the insulin-secretion-
antagonizing peptide CGRP (calcitonin-
gene-related peptide) (Figure 1). Thus,
TRPV1 deficiency prevents the age-
related decline in insulin secretion to
improve metabolism. Notably, as direct
proof for the detrimental impact of
increased CGRP on metabolic health,
the authors show that chronic infusion of
CGRP receptor antagonist in aged mice
is sufficient to restore the age-related
loss of circadian rhythm regulation of res-
piratory exchange. Further studies will
have to address whether CGRP antago-
nism also improves glucose metabolism
during aging and whether it can confer
longevity.
Intriguingly, despite an improvement of
glucose tolerance and of glucose-stimu-
lated insulin secretion, TRPV1 deficient
mice are already less sensitive to insulin
Figure 1. Disrupting a Pain Pathway Promotes Longevity
The work of Riera et al. (2014) reveals that deficiency in TRPV1, an ion channel involved in sensing pain,
leads to a decrease in circulating levels of calcitonin gene-related peptide (CGRP) and to an increase in
insulin secretion with aging. Improvement of insulin release from pancreatic beta cells is associated with a
youthful metabolism at old age as well as an extension of longevity and an improvement of cognition. In
both C. elegans and in the dorsal root ganglion (DRG) of mice, calcium influx secondary to TRPV1-acti-
vation initiates calcineurin (CaN)-dependent dephosphorylation of CREB-regulated transcription co-
activator 1 (CRTC1). Subsequent to its dephosphorylation, CRTC1 translocates to the nucleus where it
initiates the transcription through activation of the cAMP response element-binding protein (CREB).
Inactivation of the CRTC1/CREB pathway, as occurs in the absence of TRPV1, has been previously shown
to directly increase lifespan. In addition to the neuroendocrine circuitry demonstrated, further studies will
need to address the specific involvement of insulin resistance and of reduced inflammation reported in
TRPV1-deficient mice in their long-lived phenotype. Additionally, the specific role of TRPV1 within the
hypothalamus and the hippocampus in the regulations ofmetabolism and cognition, respectively, requires
further investigation.at a young age, and this insulin-resistance
worsens with age. This resistance to the
glucose regulatory effects of insulin is
not associated with detectable alterations
of insulin-stimulated AKT activation in keyinsulin-sensitive tissues such as skeletal
muscle and liver. Thus, further studies
will have to reveal the exact site(s) where
insulin resistance develops in the absence
of TRPV1 and whether this insulin resis-Cell 1tance may also contribute to the longevity
observed in these mice independent
from CGRP-mediated control of insulin
secretion (Figure 1).
Along the same line, the authors report
a tendency toward a beneficial effect of
TRPV1 deletion on the aging-associated
activation of a low-grade inflammatory
tone, both in the brain and in skel-
etal muscle, whereas inflammatory gene
expression increases in white adipose
tissue. Given the link between activated
inflammation and insulin resistance, this
may actually point to the possibility that
TRPV1 deficiency might cause insulin
resistance in adipose tissue. Moreover,
considering the emergence of inflamma-
tory signals in aging and its associated
disorders (Steculorum et al., 2014), it is
likely that this improvement of inflamma-
tory tone may also contribute to the regu-
lation of longevity. To what extent insulin-
resistance and decreased inflammation
contribute to the long-lived phenotype
of TRPV1 deficiency, still needs to be
investigated.
Interestingly, in addition to increasing
lifespan andmetabolism, TRPV1 inactiva-
tion also improves cognitive functions.
However, these experiments are per-
formed in aged animals, leaving open
the possibility that TRPV1 deficiency
improves cognition already in young ani-
mals. Notably, in the central nervous sys-
tem, TRPV1 is highly expressed in various
brain areas controlling cognitive functions
such as the cortex and the hippocampus
(Mezey et al., 2000). Although the authors
state an indistinguishable gross anatomy
of the hippocampus between TRPV1
knockout and control mice, based on
the known ability of TRPV1 to directly
modulate hippocampal synaptic plasticity
including long-term potentiation (Marsch
et al., 2007), it is likely that the improved
cognition of the TRPV1-deficient mice
may not only be secondary to the meta-
bolic youthfulness but also to a direct ef-
fect of TRPV1 on the cellular mechanisms
controlling learning and memory.
Similarly, although the authors have
elegantly described a pathway by which
TRPV1 acts on dorsal root ganglia to regu-
late insulin secretion and control meta-
bolism, TRPV1 expression is also dense
in the hypothalamus (Mezey et al., 2000).
Here, it is particularly expressed on pre-
autonomic neurons located in the57, May 22, 2014 ª2014 Elsevier Inc. 1005
paraventricular nucleus of the hypothala-
mus (PVH) that are providing projections
to the liver and those liver-related PVH
neurons are activated by the TRPV1-acti-
vator capsaicin (Gao et al., 2012). Thus,
in addition, TRPV1 may also regulate
glucose homeostasis by a direct TRPV1-
dependent modulation of the brain-liver
autonomic circuitry. Thereby, the present
study opens numerous new research ave-
nues focusing on the interplay between
aging and metabolic health through the
pleiotropic actions of TRPV1 in various
target sites.
Another aspect of TRPV1 signaling
that requires further attention is their en-
dovanilloid-dependent activation. Indeed,
considering the critical implication of
lipids in low-grade inflammation and in
the resultant neuronal and peripheral
insulin-resistance as well as cognitive
impairment, one could speculate that1006 Cell 157, May 22, 2014 ª2014 Elsevier Iactivation of TRPV1 by endovanilloid
lipids could be a mechanism at the cross-
roads of aging-associated decline in
cognition and metabolic health. Regard-
less of the endogenous ligand through
which TRPV1 limits lifespan, the availabil-
ity of potent TRPV1 antagonists opens
new therapeutic possibilities to improve
longevity and forestall the onset of age-
related disease.REFERENCES
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To provide broad immunity to a vast array of foreign antigens with a limited number of T lympho-
cytes, each cell has to recognizemany targets. By implementing a strategy to identify T cell receptor
(TCR) ligands and investigating at a fine granularity their structure and sequence relationship,
Birnbaum et al. demonstrate the surprisingly tight focus of such T cell cross-reactivity.The immune system must mount specific
host-protective responses to a large vari-
ety of pathogens. CD4+ and CD8+ T cells
contribute to host defense by employing
clonally distributed heterodimeric (ab)
receptors (TCRs) to recognize pathogen-
derived peptides presented on host cells
by major histocompatibility complex-en-
coded molecules (pMHCs). As a result of
nucleotide insertions and somatic recom-
bination of gene segments, the potential
combinatorial diversity of the TCR reper-
toire exceeds 1020 (Zarnitsyna et al.,
2013). This staggering theoretical diver-sity is tempered, however, by the fact
that each individual can only possess
at one time a tiny subset of possible
TCRs—at most equal to the total number
of T cells, 1011 for humans and 108 for
mice. Nevertheless, the actual diversity
is sufficient to respond to at least one
antigen expressed by any of a universe
of pathogens, avoiding repertoire holes
that pathogens could exploit. The obvious
implication is that every TCR must
recognize many distinct pMHC ligands
(Mason, 1998). This notion is consistent
with a large body of experimental evi-dence involving studies of individual
T cell clones, analysis of T cell develop-
ment in the thymus that requires selection
by self-peptides, and responses of T cells
to modified versions of their nominal
agonist peptide ligands (Morris and Allen,
2012).
Although cross-reactivity in TCR
recognition is widely accepted, answers
to two key questions have eluded the
field (Figure 1): what is the actual extent
of such cross-reactivity for any particular
TCR, and is there a pattern to such
cross-reactivity? In this issue of Cell,
